<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article3</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/CHARISMA" style="display:block; margin-bottom:10px;">CHARISMA Original</a></li>
<h2><strong>CHARISMA</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Clopidogrel plus Aspirin versus Aspirin Alone in High-Risk Patients". The New England Journal of Medicine. 2006. 354(16):1706-1717. PubMed • Full text • PDF <br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does dual antiplatelet therapy with clopidogrel plus low-dose aspirin improve outcomes in a broad population of patients at high risk for atherothrombotic events compared to aspirin alone?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In a broad population of high-risk patients, dual antiplatelet therapy with clopidogrel plus low-dose aspirin did not significantly reduce the rate of myocardial infarction, stroke, or death from cardiovascular causes compared to aspirin alone. There was a suggestion of harm in patients with multiple risk factors and only a marginal benefit in patients with established cardiovascular disease.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Dual antiplatelet therapy with clopidogrel and aspirin had not been widely tested in patients at high risk for atherothrombotic events beyond those with acute coronary syndromes or undergoing angioplasty.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Current guidelines do not generally recommend dual antiplatelet therapy for a broad high-risk population outside specific indications like acute coronary syndrome or percutaneous coronary intervention.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial <br/>
- N=15,603<br/>
- Clopidogrel (75 mg per day) plus low-dose aspirin (75-162 mg per day), n=7802<br/>
- Placebo plus low-dose aspirin (75-162 mg per day), n=7801<br/>
- Median follow-up: 28 months<br/>
- Analysis: Intention-to-treat<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion Criteria: Patients 45 years or older with clinically evident cardiovascular disease or multiple atherothrombotic risk factors<br/>
- Exclusion Criteria: Use of long-term oral antithrombotic medications or nonsteroidal antiinflammatory drugs; planned revascularization; established indications for clopidogrel therapy<br/>
<br/>
Baseline Characteristics<br/>
- Median age: 64 years, 29.8% female<br/>
- Patients with established cardiovascular disease: over 75%<br/>
- Patients with multiple atherothrombotic risk factors: remaining percentage<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Patients were randomized to either clopidogrel plus aspirin or placebo plus aspirin.<br/>
- Standard therapy, including statins and ACE inhibitors, was administered at the discretion of the investigator.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary Outcome: Composite of myocardial infarction, stroke, or death from cardiovascular causes <br/>
  - Clopidogrel: 6.8%, Placebo: 7.3% (RR 0.93; 95% CI, 0.83 to 1.05; P=0.22)<br/>
- Secondary Outcomes: Composite of primary outcome or hospitalization for unstable angina, transient ischemic attack, or revascularization<br/>
  - Clopidogrel: 16.7%, Placebo: 17.9% (RR 0.92; 95% CI, 0.86 to 0.995; P=0.04)<br/>
  - Severe bleeding: Clopidogrel: 1.7%, Placebo: 1.3% (P=0.09)<br/>
  - Moderate bleeding: Clopidogrel: 2.1%, Placebo: 1.3% (P&lt;0.001)<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
The trial was sponsored and funded by Sanofi-Aventis and Bristol-Myers Squibb. Dr. Topol was supported by grants from the National Institutes of Health.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/><p></p>
</div>
</div>
</div>
</div>
</body>
</html>
